Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
Status:
Recruiting
Trial end date:
2022-08-23
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics, safety, and tolerability of single and multiple
doses of intravenous ceftazidime-avibactam in hospitalized infants and neonates from 26 weeks
gestation to 3 months of age. In Part A of the study all patients will receive a single dose
of ceftazidime-avibactam. In Part B all patients will received multiple doses of
ceftazidime-avibactam. Efficacy will be assessed in the infants and neonates receiving
multiple doses of ceftazidime-avibactam.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
Allergan
Treatments:
Avibactam Avibactam, ceftazidime drug combination Ceftazidime